Related Experiment Video
Updated: Jun 23, 2025
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Landscape and Treatment Options of Shapeshifting Small Cell Lung Cancer
Yijun Gu1, Claudia A Benavente1,2,3
1Department of Pharmaceutical Sciences, University of California, Irvine, CA 92697, USA.
Small cell lung cancer (SCLC) is a complex malignancy with diverse subtypes. Understanding these subtypes and their genomic landscape is crucial for developing novel therapies beyond current chemotherapies and immune checkpoint inhibitors.
Area of Science:
- Oncology
- Genomics
- Immunology
Background:
- Small cell lung cancer (SCLC) is an aggressive neuroendocrine tumor with poor prognosis.
- Current treatments for SCLC, including chemotherapy and immune checkpoint inhibitors, offer limited efficacy.
- High tumor heterogeneity in SCLC contributes to varied patient responses and early relapse.
Purpose of the Study:
- To review the current understanding of SCLC's genomic landscape.
- To explore the characteristics and therapeutic vulnerabilities of different SCLC molecular subtypes.
- To highlight promising novel therapeutic agents in clinical development for SCLC.
Main Methods:
- Literature review integrating recent findings on SCLC genomics.
- Analysis of molecular subtypes based on transcription factor and immune gene expression.
- Compilation of data on drugs currently in clinical trials for SCLC.
Main Results:
- SCLC exhibits significant intratumoral and intertumoral heterogeneity.
- Molecular subtypes (e.g., ASCL1, NEUROD1, POU2F3, YAP1) show distinct differentiation and immune profiles.
- Several novel therapeutic targets and drugs are under investigation, showing promise for improved SCLC treatment.
Conclusions:
- Tailoring treatment strategies based on SCLC molecular subtypes is essential.
- Further research into SCLC's genomic and immune landscape will drive the development of effective therapies.
- Emerging drugs in clinical trials offer new hope for patients with this challenging cancer.
More Related Videos
08:54Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy
Published on: May 8, 2018
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers